Key facts
- It has raised $14.3M; the latest was Early Stage VC ($14.3M) in Jan 2026.
- Notable investors include Lapam Capital, Tailong VC, Hangzhou Capital, Shanghai Healthcare Capital, Jingjie Investment — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Biyo Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Biyo Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biyo Pharma
Developer of innovative drug designed for nervous system disease. The company focuses on the research and development of nervous system disease related drugs for episodic migraine and chronic migraine symptoms, providing patients with better medical treatment.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Employees
- 5
- Website
- biyopharma.com/
- Ownership
- Privately Held (backing)
Biyo Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biyo Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biyo Pharma in its N-PORT filings yet. We sweep new filings monthly.